Predictions
Trevena Inc.
Start price
Target price
Perf. (%)
€49.08
04.12.20
04.12.20
€55.00
28.04.21
28.04.21
23.84%
09.02.21
09.02.21
Could be very worthwhile Investment >20% year
Oramed Pharmaceuticals
Start price
Target price
Perf. (%)
€3.58
04.12.20
04.12.20
-
04.12.21
04.12.21
282.12%
05.12.21
05.12.21
Probably not worthwhile Investment
Revenue decline/stagnation expected
EBIT decline/stagnation expected
Lower EBIT Margin than peer group
iRhythm Technologies Inc
Start price
Target price
Perf. (%)
€151.00
02.12.20
02.12.20
-
02.12.21
02.12.21
-42.05%
03.12.21
03.12.21
Risky Investment
Corbus Pharmaceuticals Holding Inc.
Start price
Target price
Perf. (%)
€46.50
01.12.20
01.12.20
€90.00
01.12.21
01.12.21
-27.97%
14.12.20
14.12.20
Could be worthwhile Investment >10% per year
Very bad culture
No uniques
Below average Management
Enzon Pharmaceuticals
Start price
Target price
Perf. (%)
€0.12
01.12.20
01.12.20
€0.000
01.12.21
01.12.21
49.17%
14.12.20
14.12.20
Could be worthwhile Investment >10% per year
Larimar Therapeutics Inc.
Start price
Target price
Perf. (%)
€17.12
01.12.20
01.12.20
€20.00
01.12.21
01.12.21
5.26%
14.12.20
14.12.20
Could be worthwhile Investment >10% per year
Jaguar Health Inc.
Start price
Target price
Perf. (%)
€85.50
01.12.20
01.12.20
€225.00
01.12.21
01.12.21
-28.42%
14.12.20
14.12.20
Could be worthwhile Investment >10% per year
Genmark Diagnostics
Start price
Target price
Perf. (%)
€11.10
30.11.20
30.11.20
€14.00
30.11.21
30.11.21
-7.21%
14.12.20
14.12.20
Could be worthwhile Investment >10% per year
Pacific Biosciences of California Inc.
Start price
Target price
Perf. (%)
€13.50
30.11.20
30.11.20
€15.00
30.11.21
30.11.21
31.85%
14.12.20
14.12.20
Could be worthwhile Investment >10% per year
Cutera Inc.
Start price
Target price
Perf. (%)
€21.00
30.11.20
30.11.20
€25.00
30.11.21
30.11.21
-15.71%
14.12.20
14.12.20
Could be very worthwhile Investment >20% year
CHF Solutions Inc
Start price
Target price
Perf. (%)
-
30.11.20
30.11.20
€7.00
30.11.21
30.11.21
-
14.12.20
14.12.20
Could be very worthwhile Investment >20% year
Pfizer Inc.
Start price
Target price
Perf. (%)
€31.50
30.11.20
30.11.20
€38.00
30.11.21
30.11.21
18.40%
02.08.21
02.08.21
Could be worthwhile Investment >10% per year
Very high dividend yield expected
Fair valuation
Higher EBIT margin than peer group
Viracta Therapeutics Inc.
Start price
Target price
Perf. (%)
€6.65
30.11.20
30.11.20
€10.50
30.11.21
30.11.21
-21.05%
14.12.20
14.12.20
Innovative
Could be worthwhile Investment >10% per year
Good culture
No uniques
Oramed Pharmaceuticals
Start price
Target price
Perf. (%)
€6.18
30.11.20
30.11.20
€8.00
30.11.21
30.11.21
-22.65%
30.11.20
30.11.20
Could be worthwhile Investment >10% per year
Fair valuation
Capable Management
Risky balance sheet
Inovio Pharma
Start price
Target price
Perf. (%)
€10.60
29.11.20
29.11.20
€12.00
29.11.21
29.11.21
-11.79%
10.12.20
10.12.20
Very low/no dividend yield expected
Risky balance sheet
ROE lower than 10% per year
Increased challenges to pay loans and raise capital
Revance Therapeutics Inc.
Start price
Target price
Perf. (%)
€19.50
28.11.20
28.11.20
€23.00
28.11.21
28.11.21
-36.41%
01.11.21
01.11.21
Could be worthwhile Investment >10% per year
Axonics Modulation Technologies Inc
Start price
Target price
Perf. (%)
€37.20
28.11.20
28.11.20
€42.00
28.11.21
28.11.21
31.72%
29.11.21
29.11.21
Could be worthwhile Investment >10% per year
Shanghai Fosun Pharmaceutical Group Co Ltd
Start price
Target price
Perf. (%)
€3.58
28.11.20
28.11.20
-
28.11.21
28.11.21
29.47%
29.11.21
29.11.21
Could be worthwhile Investment >10% per year
Known brand
Veeva Systems A
Start price
Target price
Perf. (%)
€230.05
28.11.20
28.11.20
-
28.11.21
28.11.21
12.50%
29.11.21
29.11.21
Could be worthwhile Investment >10% per year
Differentiated customer and product portfolio
Medium risks for its business
Nanorepro AG
Start price
Target price
Perf. (%)
€3.38
26.11.20
26.11.20
-
16.11.21
16.11.21
198.22%
17.11.21
17.11.21
Could be worthwhile Investment >10% per year
Standard Investments for future growth
Revenue growth >5% per year expected
Lower EBIT Margin than peer group
Cocrystal Pharma Inc.
Start price
Target price
Perf. (%)
€13.68
24.11.20
24.11.20
-
24.11.21
24.11.21
-18.86%
02.06.21
02.06.21
Probably not worthwhile Investment